Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
2.
Klin Padiatr ; 223(4): 209-13, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21509704

ABSTRACT

BACKGROUND: Mycoplasma pneumoniae is an important aetiological agent of encephalitis in children, with encephalitis being the most frequent paediatric extrapulmonary manifestation of M. pneumoniae infections. Evidence of M. pneumoniae involvement in childhood encephalitis is difficult to obtain, because M. pneumoniae is seldom detected in the cerebrospinal fluid and the clinical picture shows gradual onset. Therefore, we present a small case-study as a paradigm of M. pneumoniae-associated encephalitis in childhood and illustrate the importance of this entity based on a review of previously published cases. PATIENTS: We describe neurological signs and symptoms of 2 patients with M. pneumoniae-associated encephalitis in childhood. Respiratory symptoms with fever occurred in both children. They were seropositive for M. pneumoniae, but did not have the organism detected by PCR from cerebrospinal fluid. No long-term neurologic sequelae occurred. CONCLUSION: M. pneumoniae has to be considered as a responsible pathogen of encephalitis in children, even if respiratory symptoms do not occur. Due to the seldom detection of M. pneumoniae in cerebrospinal fluid, evidence of m. pneumoniae involvement in childhood encephalitis is difficult to obtain.Faced with a neurological disease with no organism detected in CNS in the majority of cases assumes that M. pneumoniae-associated encephalitis is most likely a paradigm for an autoimmune disease with uniform pathogenesis mediated by an immunologic response to an antecedent antigenic stimulus from M. pneumoniae. It is important to relate this organism to this relatively common and potentially devastating clinical syndrome.


Subject(s)
Encephalitis/diagnosis , Mycoplasma Infections/diagnosis , Mycoplasma pneumoniae , Pneumonia, Mycoplasma/diagnosis , Anti-Bacterial Agents/therapeutic use , Cerebrospinal Fluid/microbiology , Child , Child, Preschool , Diagnosis, Differential , Drug Therapy, Combination , Encephalitis/drug therapy , False Negative Reactions , Female , Humans , Male , Mycoplasma Infections/drug therapy , Neurologic Examination , Pneumonia, Mycoplasma/drug therapy , Polymerase Chain Reaction
4.
Praxis (Bern 1994) ; 99(1): 61-5, 2010 Jan 06.
Article in German | MEDLINE | ID: mdl-20052641

ABSTRACT

Ramsay Hunt syndrome (RHS) is defined as a peripheral facial nerve palsy accompanied by an erythematous vesicular rash on the ear (zoster oticus) and hard palate. It is known that varicella zoster virus (VZV) causes RHS. History and neurological examination remain the mainstay of diagnosis. Prednisolone and acyclovir/valacyclovir is helpful in RHS when given within three days of onset. We report on a 14-year-old boy who had RHS accompanied by meningitis. Polymerase chain reaction identified VZV in exudates from the geniculate zone of the ear, the hard palate and in the CSF.


Subject(s)
Bell Palsy/diagnosis , Herpes Zoster Oticus/diagnosis , Palate, Hard , Adolescent , Anti-Inflammatory Agents/therapeutic use , Bell Palsy/drug therapy , Diagnosis, Differential , Follow-Up Studies , Herpes Zoster Oticus/drug therapy , Humans , Male , Prednisolone/therapeutic use
7.
Schweiz Med Wochenschr ; 130(43): 1581-9, 2000 Oct 28.
Article in German | MEDLINE | ID: mdl-11100511

ABSTRACT

UNLABELLED: Renal transplantation is the treatment of choice for paediatric patients with end-stage renal failure. Living donor transplantation (LDT) has become an important therapeutic option due to the shortage of cadaver donors and increasingly long waiting times. METHODS: Between 1992 and 1999, a total of 48 paediatric and adolescent patients underwent renal transplantation in Zurich. Of these, 21 patients (44%) received a kidney from a living related donor. 11 patients had been dialysed before LDT over a period of 0.2-5.7 years (median 0.6), and 10 were transplanted preemptively. Triple immunosuppression consisted of cyclosporine A, azathioprine or mycophenolate mofetil (MMF; since 1998), and prednisone. The observation period was 0.5-7.3 years (median 2). RESULTS: Recipients were 2-18 (median 10.5) years old at transplantation. One third had either a congenital malformation, an inherited disease, or an acquired disorder. One patient died of an associated cardiac disease at 4 months with functioning graft, and one functional graft loss occurred after 2.8 years. 9 patients were switched from cyclosporine to tacrolimus, 7 for biopsy-proven rejection and 2 for cosmetic reasons (hypertrichosis). No antibody preparations were used. Median glomerular filtration rate (51Cr-EDTA), measured after one year in 11 donor/recipients, was 64 (55-95) and 54 (32-82) ml/min/1.73 m2, respectively. The most recent estimated renal function (Schwartz formula) of 19 functioning grafts was 37-79 ml/min/1.73 m2 (median 63). Median body height of 16 patients with no associated extrarenal disease was -0.9 SDS (standard deviation score); the remaining 3--with serious extra-renal disease--were considerably growth retarded. Main complications were reversible rejection episodes in 19 (90%), arterial hypertension (16), CMV disease (2) and asymptomatic CMV infection (3), pyelonephritis (3), and recurrence of the primary renal disease, seizures, diabetes mellitus and non-compliance (one each). Actuarial patient and graft survival (Kaplan-Meier) after 3 years was 95 and 83% respectively. This was not statistically different from the cadaveric donor group (n = 27) with 100 and 80% survival respectively. Overall rehabilitation was excellent. The donors were 12 mothers, 8 fathers and one grandmother aged 31 to 50 (median 39) years; none of them experienced serious postoperative problems. CONCLUSIONS: The paediatric transplantation programme would no longer be feasible in Switzerland without LDT. The results are very encouraging; preemptive transplantation makes it possible to avoid dialysis in half of the patients. The risk for the donor is small, and careful evaluation without putting pressure on the family is essential.


Subject(s)
Graft Survival , Kidney Transplantation/statistics & numerical data , Living Donors , Adolescent , Adult , Cadaver , Child , Child, Preschool , Female , Follow-Up Studies , Glomerular Filtration Rate , Humans , Infant , Kidney Failure, Chronic/surgery , Kidney Transplantation/mortality , Kidney Transplantation/physiology , Living Donors/statistics & numerical data , Male , Middle Aged , Retrospective Studies , Survival Rate , Switzerland , Tissue Donors/supply & distribution
8.
Pediatr Nephrol ; 14(8-9): 713-6, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10955913

ABSTRACT

We report two pediatric patients with end-stage renal failure who developed heparin-induced thrombocytopenia type II (HIT II) on hemodialysis (HD). Both developed acute respiratory distress and chest pain within 30 min of initiating the 5th HD session. The platelets dropped during HD from 168 to 38x10(9)/l and from 248 to 109x10(9)/l, respectively. Marked clots were observed in the dialyzers. Substitution of heparin with the low molecular weight heparin dalteparin had no effect. Switching from anticoagulation to the heparinoid danaparoid resulted in immediate disappearance of all adverse effects, and further long-term HD was uneventful. HIT II was diagnosed clinically; heparin-induced platelet activation test (HIPA) and serum IgG, IgA, and IgM to heparin-platelet factor 4 complexes (HPF4) were both negative. We conclude that HIT II may occur in children on HD. HIT II is essentially a clinical diagnosis, as HIPA and antibodies to HPF4 are not always positive. Once HIT II is suspected, heparin (and low-molecular-weight heparins) should be stopped immediately. Long-term anticoagulation with danaparoid is a valuable option for patients on HD.


Subject(s)
Anticoagulants/therapeutic use , Chondroitin Sulfates/therapeutic use , Dermatan Sulfate/therapeutic use , Heparin/adverse effects , Heparitin Sulfate/therapeutic use , Kidney Failure, Chronic/therapy , Renal Dialysis/adverse effects , Thrombocytopenia/chemically induced , Adolescent , Anticoagulants/adverse effects , Child , Dalteparin/adverse effects , Drug Combinations , Humans , Male , Platelet Count
9.
Praxis (Bern 1994) ; 87(47): 1593-9, 1998 Nov 19.
Article in German | MEDLINE | ID: mdl-9865130

ABSTRACT

Since 1985, 20 children have been followed with early onset of chronic renal failure (plasma creatinine > 120 mumol/l in first year of life). So far, 10 and 7 patients underwent peritoneal dialysis and renal transplantation, respectively. The aim of this study was to assess the overall costs. The recorded costs comprised both the direct costs of dialysis and transplantation, and the costs of all medical and psychosocial measures. The annual median costs of conservative treatment, peritoneal dialysis, the year of transplantation, and follow-up after transplantation amounted to 30,000, 93,000, 130,000 and 28,000 Swiss francs, respectively. The youngest patients caused the highest expenses. The active treatment permitted not only survival, but--in most patients--also a normal cognitive and psychosocial development.


Subject(s)
Kidney Failure, Chronic/economics , Adolescent , Child , Child, Preschool , Costs and Cost Analysis , Female , Follow-Up Studies , Humans , Infant , Infant, Newborn , Kidney Failure, Chronic/rehabilitation , Kidney Transplantation/economics , Male , Peritoneal Dialysis/economics , Switzerland
SELECTION OF CITATIONS
SEARCH DETAIL
...